1st-line mFOLFOXIRI + panitumumab vs FOLFOXIRI treatment of RAS wt mCRC: A randomized phase II VOLFI trial of the AIO (KRK-0109)
نویسندگان
چکیده
منابع مشابه
Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer (mCRC): AIO KRK-0104 trial.
3589 Background: The AIO KRK-0104 randomized phase II trial investigated the efficacy and safety of two capecitabine-based regimens: CAPIRI plus cetuximab (CAPIRI-C) and CAPOX plus cetuximab (CAPOX-C) in the first-line treatment of metastatic colorectal cancer (mCRC). Treatment related skin toxicity was evaluated separately for capecitabine and cetuximab. The present analysis investigates the c...
متن کاملPrimary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies
Background Previous studies have reported the prognostic impact of primary tumor sidedness in metastatic colorectal cancer (mCRC) and its influence on cetuximab efficacy. The present retrospective analysis of two panitumumab trials investigated a possible association between tumor sidedness and treatment efficacy in first-line mCRC patients with RAS wild-type (WT) primary tumors. Materials an...
متن کاملthe washback effect of discretepoint vs. integrative tests on the retention of content in knowledge tests
در این پایان نامه تاثیر دو نوع تست جزیی نگر و کلی نگر بر به یادسپاری محتوا ارزیابی شده که نتایج نشان دهندهکارایی تستهای کلی نگر بیشتر از سایر آزمونها است
15 صفحه اولGenomic markers of panitumumab resistance including ERBB2/HER2 in a phase II study of KRAS wild-type (wt) metastatic colorectal cancer (mCRC)
A prospective study was conducted to identify biomarkers associated with resistance to panitumumab monotherapy in patients with metastatic colorectal cancer (mCRC). Patients with previously treated, codon 12/13 KRAS wt, mCRC were prospectively administered panitumumab 6 mg/kg IV q2weeks. Of 34 panitumumab-treated patients, 11 (32%) had progressive disease at 8 weeks and were classified as non-r...
متن کامل629plapatinib versus Lapatinib plus Capecitabine as Second-line Treatment in Her2-overexpressing Metastatic Gastro-esophageal Cancer (gc): a Randomized Phase Ii Trial of the Arbeitsgemeinschaft Internistische Onkologie (aio).
S. Lorenzen1, U. Helbig2, J. Riera-Knorrenschild3, G.M. Haag4, M. Pohl5, P. C. Thuss-Patience6, F. Bassermann1, F. Weißinger7, E. Schnoy8, K. Becker9, J. Rüschoff10, A. Eisenmenger11, I. Karapanagiotou-Schenkel11, F. Lordick12 3rd Department of Internal Medicine (hematology/medical Oncology), Klinikum Rechts der Isar, Technische Universität München, Munich, GERMANY 3rd Medical Department, Hemat...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2018
ISSN: 0923-7534
DOI: 10.1093/annonc/mdy281.001